Dublin-headquartered Horizon Therapeutics has submitted a planning application to grow its development and manufacturing facility in Waterford, Ireland. The move, designed to load new drug substance biologics development and manufacturing firepower, will add another 320,000 square feet to the plant’s existing 44,000-square-foot fill-finish facility. The upgrade is expected to create around 350 new jobs.

As work with Irish and U.S. regulators rolls on, Horizon expects to obtain licensure for sterile-fill finish production and anticipates the first medicine to be approved for release from the existing facility in 2023.